Federico J Mensa Selected Research

Ribavirin (Virazole)

10/2019	Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
1/2019	Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
10/2018	Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
1/2018	Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
1/2018	High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
10/2017	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
1/2017	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
10/2016	High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
8/2016	Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
1/2016	HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Federico J Mensa Research Topics

Disease

32	Infections 01/2021 - 01/2013
20	Fibrosis (Cirrhosis) 01/2020 - 02/2015
14	Chronic Hepatitis C 01/2019 - 08/2013
5	Liver Diseases (Liver Disease) 10/2019 - 10/2017
3	Virus Diseases (Viral Diseases) 01/2021 - 02/2015
2	COVID-19 03/2024 - 01/2023
2	Chronic Renal Insufficiency 10/2019 - 10/2017
1	Myocarditis (Carditis) 03/2024
1	Pericarditis 03/2024
1	Persistent Infection 01/2019
1	Mental Disorders (Mental Disorder) 01/2019
1	Flushing 01/2019
1	Nausea 01/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 02/2015
1	Anemia 01/2015
1	Exanthema (Rash) 01/2013
1	Asthenia 01/2013
1	Pruritus (Itching) 01/2013

Drug/Important Bio-Agent (IBA)

24	glecaprevir and pibrentasvirIBA 01/2020 - 01/2017
15	Ribavirin (Virazole)FDA LinkGeneric 10/2019 - 01/2013
14	Antiviral Agents (Antivirals)IBA 01/2021 - 01/2013
13	InterferonsIBA 01/2019 - 01/2013
12	glecaprevirIBA 10/2019 - 10/2016
11	pibrentasvirIBA 10/2019 - 10/2016
7	Protease Inhibitors (Protease Inhibitor)IBA 01/2018 - 08/2013
7	deleobuvirIBA 08/2016 - 01/2013
7	faldaprevirIBA 08/2016 - 01/2013
6	SofosbuvirIBA 01/2019 - 10/2017
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2019
2	NucleosidesIBA 08/2016 - 01/2015
1	Messenger RNA (mRNA)IBA 03/2024
1	mRNA VaccinesIBA 03/2024
1	BNT162 VaccineIBA 03/2024
1	VaccinesIBA 01/2023
1	P-300IBA 08/2019
1	AcidsIBA 01/2019
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2019
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2019
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2019
1	Reducing AgentsIBA 01/2019
1	daclatasvirIBA 01/2018
1	Proton Pump InhibitorsIBA 12/2017
1	trichostatin A (A 300)IBA 01/2017
1	Inosine TriphosphataseIBA 01/2015

Therapy/Procedure

8	Therapeutics 01/2019 - 08/2013
1	Opiate Substitution Treatment 01/2019
1	Retreatment 01/2019
1	Polypharmacy 01/2019
1	Duration of Therapy 01/2018